AZTA logo

Azenta, Inc. Stock Price

NasdaqGS:AZTA Community·US$1.6b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 5 Fair Values set on narratives written by author

AZTA Share Price Performance

US$35.05
-11.79 (-25.17%)
US$39.83
Fair Value
US$35.05
-11.79 (-25.17%)
12.0% undervalued intrinsic discount
US$39.83
Fair Value
Price US$35.05
AnalystConsensusTarget US$39.83

AZTA Community Narratives

AnalystConsensusTarget·
Fair Value US$39.83 12.0% undervalued intrinsic discount

AZTA: Biopharma Demand and Acquisition Focus Will Drive Shares Higher Through 2026

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative

Trending Discussion

Updated Narratives

AZTA logo

AZTA: Mid-Single-Digit Organic Revenue Acceleration Will Broaden Profit Margins Into 2026

Fair Value: US$39.83 12.0% undervalued intrinsic discount
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and slightly overvalued.

1 Risk
3 Rewards

Azenta, Inc. Key Details

US$593.8m

Revenue

US$323.5m

Cost of Revenue

US$270.3m

Gross Profit

US$245.9m

Other Expenses

US$24.5m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
0.53
45.52%
4.12%
0%
View Full Analysis

About AZTA

Founded
1978
Employees
3000
CEO
John P. Marotta
WebsiteView website
www.azenta.com

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, synthesis editing, and related services. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

Recent AZTA News & Updates

Azenta's (NASDAQ:AZTA) Earnings Offer More Than Meets The Eye

Nov 28
Azenta's (NASDAQ:AZTA) Earnings Offer More Than Meets The Eye

Recent updates

No updates